The 1024 channel digital correlator receiver of the Gauribidanur radioheliograph

R. Ramesh,M. Rajan,Ch. V. Sastry

DOI: https://doi.org/10.1007/S10686-006-9065-Y

2006-08-30

Abstract:

What problem does this paper attempt to address?

Initial clinical experience of vasodilatory effect of intra-cisternal infusion of magnesium sulfate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage

Kentaro Mori,Takuji Yamamoto,Yasuaki Nakao,Hideo Osada,Yasukazu Hara,Kazutaka Oyama,Takanori Esaki

DOI: https://doi.org/10.2176/nmc.49.139

Abstract:The vasodilatory effect of intra-cisternal infusion of magnesium sulfate solution was evaluated in 10 patients with symptomatic vasospasm after aneurysmal subarachnoid hemorrhage (SAH) who underwent early clipping surgery. Cisternal drainage was installed in the prepontine and/or sylvian fissures. Carotid angiography was performed immediately after the onset of symptomatic vasospasm, then intra-cisternal infusion of 15 mmol/l magnesium sulfate in Ringer solution was started at 20 ml/hr and continued until day 14. Irrigation was performed from the cisternal tube (inlet) to the spinal drainage (outlet). The cerebrospinal fluid magnesium ion concentration (1.2 +/- 0.2 mEq/l) significantly increased after the infusion therapy (6.0 +/- 1.7 mEq/l, p < 0.001). Repeat angiography showed vasodilatory effect on the spastic cerebral arteries at 3 hours after the infusion, especially in the arteries near to the site of cisternal drainage placement. The magnesium infusion also caused decreased mean arterial blood velocity in the spastic arteries in 6 of the 7 measured patients (162 +/- 38 cm/sec to 114 +/- 42 cm/sec, p < 0.001). Finally, 5 of the 10 patients achieved good recovery, 1 patient had moderate disability, 1 patient became severely disabled due to meningitis, and 3 patients were vegetative or dead, due to failure of magnesium irrigation in 1 patient and advanced age in the other 2 (more than 80 years old). This preliminary study indicates that intra-cisternal infusion of magnesium sulfate solution has vasodilatory effect on the spastic cerebral arteries after aneurysmal SAH.
Association between third molar agenesis and craniofacial structure development.

Jara Ramiro-Verdugo,Elena De Vicente-Corominas,J. Montiel-Company,J. Gandía-Franco,C. Bellot-Arcís

DOI: https://doi.org/10.1016/j.ajodo.2015.05.025

IF: 2.711

2015-11-01

American Journal of Orthodontics and Dentofacial Orthopedics

Abstract:
Effect of intrathecal magnesium sulfate solution injection via a microcatheter in the cisterna magna on cerebral vasospasm in the canine subarachnoid haemorrhage model

Kentaro Mori,Takuji Yamamoto,Masahiro Miyazaki,Yasukazu Hara,Yasuhisa Aiko,Nobuhiro Koike,Shinsuke Sakamoto,Yasuaki Nakao,Takanori Esaki

DOI: https://doi.org/10.3109/02688697.2011.591948

Abstract:Objective: To evaluate intracisternal injection of magnesium sulfate (MgSO(4)) solution via a lumbar catheter for the treatment of cerebral vasospasm in the canine subarachnoid haemorrhage (SAH) model. Materials and methods: SAH was induced in 7 beagle dogs using the dual haemorrhage model. Vertebral angiography was repeated on Day 1 (before SAH), and on Day 7 (during cerebral vasospasm) before and 1.5 hours after injection of 0.5 mL/kg of 15 mmol/L MgSO(4) in Ringer solution via the tip of a microcatheter placed in the cisterna magna from the lumbar spine. Results: After injection of MgSO(4) solution, the cerebrospinal fluid magnesium ion concentration significantly increased to 3.89 ± 0.97 mEq/L (P < 0.01) from the baseline value (1.49 ± 0.07 mEq/L). The arterial diameters of the basilar artery (BA), vertebral artery (VA), and superior cerebral artery (SCA) on Day 1 were 1.26 ± 0.19 mm, 1.10 ± 0.13 mm, and 0.74 ± 0.21 mm, respectively. On Day 7 before injection, the arterial diameters of the BA, VA, and SCA significantly decreased to 0.75 ± 0.27 mm, 0.74 ± 0.25 mm, and 0.36 ± 0.21 mm, respectively (P < 0.01), due to vasospasm, and were significantly increased to 0.91 ± 0.27 mm (P < 0.01), 0.91 ± 0.31 mm (P < 0.05), and 0.54 ± 0.14 mm (P < 0.01), respectively, after intracisternal injection of MgSO(4) solution. Conclusions: Intracisternal MgSO(4) therapy using a microcatheter from the lumbar spine may be effective against vasospasm in the clinical setting of endovascular treatment of ruptured aneurysm.
Effects of intrathecal magnesium sulfate in severe pre- eclampsia patients undergoing cesarean section

xiao fei,chen xinzhong,xu wenping,zhang wangping,zhang xiaomin,wang lizhong

DOI: https://doi.org/10.14109/j.cnki.xyylc.2015.02.009

2015-01-01

Abstract:AIM To study the effects of intrathecal magnesium sulfate on anesthesia in severe pre-eclampsia patients undergoing cesarean section. METHODS Sixty severe pre- eclampsia primiparas undergoing caesarean section were included and randomly divided into two groups(n = 30). The patients in the magnesium group were received spinal anesthesia with 0.5% bupivacaine 2 m L + sufentanil 2.5 μg + magnesium sulfate 50 mg and the other patients in the control group received bupivacaine and sufentanil only. Intra- operative pain was rescued by intravenous fentanyl 1 μg·kg-1. Postoperative pain was rescued by patient control intravenous analgesia(PCIA). Onset, duration of sensory and motor block, duration of spinal anesthesia and postoperative analgesia requirements were studied. The adverse drug reactions and the Apgar score of infants were observed.RESULTS The duration of spinal anesthesia((233.4 ± 17.2) min vs.(192.4 ± 12.4) min) and motor block((204.8 ± 20.1) min vs.(173.6 ± 17.5) min) were significantly longer in the magnesium group compared with the control group(P < 0.05). The VAS at 4 h time point after cesarean delivery in the magnesium group was significantly lower than that in the control group(P < 0.05). Fentanyl requirement for 24 h following surgery was significantly lower in the magnesium group than in the control group(( 157.3 ± 45.5) μg vs.( 243.5 ±48.7) μg, P < 0.05). The incidence rate of adverse drug reactions, such as hypotension, bradycardia,nausea, vomiting and pruritus, was similar between the two groups(P > 0.05). The Apgar score at 1 min and5 min after babies’ delivery was above seven points in the two groups. CONCLUSION In parturients with severe pre- eclampsia undergoing caesarean delivery, the addition of intrathecal magnesium sulfate to bupivacaine and sufentanil prolongs the duration of analgesia and reduces postoperative analgesic requirements without additional adverse drug reactions.
High fibre diet in symptomatic diverticular disease of the colon.

A. Leahy,R. Ellis,D. Quill,A. Peel

1985-05-01

Annals of The Royal College of Surgeons of England

Abstract:Over the past decade fibre supplementation has achieved widespread acceptance in the management of symptomatic diverticular disease, although the efficacy of this treatment has been debated. We have conducted a retrospective review of 72 patients admitted to hospital with symptomatic diverticular disease over a ten year period in order to determine whether or not high fibre diet afforded protection against the development of complications, necessity for surgery or persistence of symptoms. Fifty-six patients were treated non-operatively, of these 43 received advice concerning a high fibre diet but only 31 patients complied. The 12 patients who failed to take additional fibre and the 13 patients who never received dietary advice (25 patients) formed the non high fibre group. Those treated with fibre supplementation fared significantly better in developing fewer complications and required less surgery (P less than 0.05). At the time of follow-up review patients on a high fibre diet reported significantly fewer symptoms (P less than 0.05).
Temporal profile of the effects of intracisternal injection of magnesium sulfate solution on vasodilation of spastic cerebral arteries in the canine SAH model

Kentaro Mori,Masahiro Miyazaki,Yasukazu Hara,Yasuhisa Aiko,Takuji Yamamoto,Yasuaki Nakao,Takanori Esaki

DOI: https://doi.org/10.1007/978-3-7091-0356-2_8

Abstract:Purpose: the temporal profiles of the effects of intracisternal injection of magnesium sulfate (MgSO(4)) on vasodilation and cerebrospinal fluid (CSF) magnesium ion (Mg(2+)) concentration were investigated in the canine subarachnoid hemorrhage (SAH) model. Method: cerebral vasospasm was induced using the two-hemorrhage model in seven female beagles. On day 7, 0.5 ml/kg of 15 mmol/l MgSO(4) in Ringer solution was injected into the cerebellomedullary cistern. Angiography was performed on day 1 (before SAH), and before and 1, 3, and 6 h after the intracisternal injection on day 7. CSF Mg(2+) was measured at the same time. Results: the diameters of the basilar artery (BA), vertebral artery (VA), and superior cerebellar artery (SCA) before the intracisternal injection on day 7 were 0.59 ± 0.15, 0.41 ± 0.17, and 0.35 ± 0.17 mm, respectively, and were significantly decreased (p < 0.01) compared with the baseline diameters on day 1. The BA diameters at 1 h (0.74 ± 0.16 mm) and 3 h (0.73 ± 0.13 mm), the VA diameter at 1 h (0.64 ± 0.14 mm), and the SCA diameter at 3 h (0.54 ± 0.08 mm) after the injection were significantly increased (p < 0.05). The CSF Mg(2+) concentration was significantly increased (p < 0.01) at 1 h (3.59 ± 0.76 mEq/l) and 3 h (2.00 ± 0.31 mEq/l) after the injection compared with the baseline value (1.35 ± 0.23 mEq/l). Conclusions: the reversible effect of intracisternal MgSO(4) solution injection on the spastic artery depends on maintenance of the optimal CSF Mg(2+) concentration.
[Oxidative stress in patients on regular hemodialysis and peritoneal dialysis].

J. Vostálová,A. Galandáková,P. Štrebl,J. Zadražil

2012-06-01

Abstract:Hemodialysis and peritoneal dialysis are methods of blood purification, which partially replaced excretory renal function in patients with chronic renal failure, which was depleted regime, dietary and pharmaco-therapeutic remedy, and who are not eligible for kidney transplantation. Both two methods are accompanied by increased oxidative stress. In peritoneal dialysis particularly the composition of dialysis solution contributes to oxidative stress. In extracorporeal hemodialysis the oxidative stress is associated with the character of hemodialysis membranes, non-specific loss of low molecular weight antioxidants, activation of leukocytes (oxidative burst), feroteraphy, supplementation with low molecular weight antioxidants and other factors. To improve and maintain the quality of life of dialysis patients, the continuous monitoring of oxidative stress-related parameters as non-traditional risk factors for cardiovascular complications development is suitable.
Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage

Jason J. Chang,Rocco Armonda,Nitin Goyal,Adam S. Arthur,AdamS Arthur,JasonJ Chang

DOI: https://doi.org/10.4103/1673-5374.251189

2019-01-01

Neural Regeneration Research

Abstract:Intracerebral hemorrhage (ICH) remains the second-most common form of stroke with high morbidity and mortality. ICH can be divided into two pathophysiological stages: an acute primary phase, including hematoma volume expansion, and a subacute secondary phase consisting of blood-brain barrier disruption and perihematomal edema expansion. To date, all major trials for ICH have targeted the primary phase with therapies designed to reduce hematoma expansion through blood pressure control, surgical evacuation, and hemostasis. However, none of these trials has resulted in improved clinical outcomes. Magnesium is a ubiquitous element that also plays roles in vasodilation, hemostasis, and blood-brain barrier preservation. Animal models have highlighted potential therapeutic roles for magnesium in neurological diseases specifically targeting these pathophysiological mechanisms. Retrospective studies have also demonstrated inverse associations between admission magnesium levels and hematoma volume, hematoma expansion, and clinical outcome in patients with ICH. These associations, coupled with the multifactorial role of magnesium that targets both primary and secondary phases of ICH, suggest that magnesium may be a viable target of study in future ICH studies.

neurosciences,cell biology
Early Intravenous Magnesium Sulfate and Its Impact on Cerebral Vasospasm as well as Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Retrospective Matched Case-Control Analysis

Julian Feulner,Cornelia S Weidinger,Arnd Dörfler,Torsten Birkholz,Michael Buchfelder,Björn Sommer

DOI: https://doi.org/10.1016/j.wneu.2024.03.062

Abstract:Background: Magnesium sulfate (MgSO4) is a potential neuroprotective agent for patients with aneurysmal subarachnoid hemorrhage (SAH). We analyzed the effect of early application of intraoperative intravenous MgSO4 and compared cerebral vasospasm (CV), delayed cerebral ischemia (DCI), and neurological outcome in 2 patient cohorts. Methods: A retrospective matched-pair analysis from patients at a single center in Germany was performed without (group A) and with (group B) MgSO4 application <24 hours after diagnosis. Pairs were matched according to the known risk factors for DCI and CV (age, Fisher grade, smoking, severity of SAH). Incidence of CV and DCI and neurological outcome using the modified Rankin Scale score 3 and 12 months after SAH were recorded. Results: The inclusion criteria were met by 196 patients. After risk stratification, 48 patients were included in the final analysis (age 54.2 ± 8.1 years; 30 women and 18 men) and were assigned to group A (n = 24) or group B (n = 24). CV occurred less frequently in group B (33%) than in group A (46%). Likewise, DCI was present in 13% in group B compared with 42% in group A. After 12 months, 22 patients in group B had a favorable functional outcome (modified Rankin Scale score 0-3) compared with 15 patients in group A. Conclusions: In this study, the incidence of CV and DCI was lower in patients receiving intravenous MgSO4 within 24 hours after aneurysmal SAH onset. Favorable functional outcome was more likely in the MgSO4 group after 12 months of follow-up.
Magnesium Protects in Episodes of Critical Perfusion after Aneurysmal SAH

Ekkehard Kunze,Nadine Lilla,Christian Stetter,Ralf-Ingo Ernestus,Thomas Westermaier

DOI: https://doi.org/10.1515/tnsci-2018-0016

2018-09-01

Abstract:Background: To analyze whether magnesium has a neuroprotective effect during episodes that indicate a critical brain perfusion after aneurysmal subarachnoid hemorrhage (SAH). Methods: 107 patients with aSAH were randomized to continuously receive intravenous magnesium sulfate with target serum levels of 2.0 - 2.5 mmol/l (n = 54) or isotonic saline (n = 53). Neurological examination and transcranial Doppler sonography (TCD) were performed daily, Perfusion-CT (PCT) was acquired in 3-day intervals, angiography in case of suspected vasospasm. The primary endpoint was the development of secondary infarction following episodes of delayed ischemic neurological deficit (DIND), elevated mean flow velocity (MFV) in TCD or pathological findings in PCT. Results: In the magnesium group, 9 episodes of DIND were registered, none was followed by secondary infarction. In the control group, 23 episodes of DIND were registered, 9 were followed by secondary infarction (p < 0.05). In the magnesium group, 114 TCD-measurements showed an elevated MFV(> 140 cm/s). 7 were followed by new infarction. In control patients, 135 measurements showed elevated MFV, 32 were followed by new infarction (p < 0.05). 10 of 117 abnormal PCT-findings were followed by new infarction, compared to 30 of 122 in the control-group (p < 0.05). Conclusion: DIND, elevated MFV in TCD and abnormal PCT are findings which are associated with an increased risk to develop delayed secondary infarction. The results of this analysis suggest that magnesium-treatment may reduce the risk to develop infarction in a state of critical brain perfusion.
The Efficacy and Safety of Nimodipine in Acute Ischemic Stroke Patients with Mild Cognitive Impairment: a Double-Blind, Randomized, Placebo-Controlled Trial

Huaguang Zheng,Yilong Wang,Anxin Wang,Hao Li,David Wang,Xingquan Zhao,Penglian Wang,Haipeng Shen,Lijun Zuo,Yuesong Pan,Zixiao Li,Xia Meng,Xianwei Wang,Weixiong Shi,Yi Ju,Liping Liu,Kehui Dong,Chunxue Wang,Rubo Sui,Rong Xue,Xiaoping Pan,Xiaoyua Niu,Benyan Luo,Yi Sui,Huali Wang,Tao Feng,Yongjun Wang

DOI: https://doi.org/10.1016/j.scib.2018.12.006

IF: 18.9

2018-01-01

Science Bulletin

Abstract:Nimodipine might be effective in subcortical vascular dementia (VaD). Its benefit in preventing further cognitive decline in patients with acute ischemic stroke (AIS) and vascular mild cognitive impairment (VaMCI) remains to be established. In this multicenter, double-blind trial, we randomly assigned 654 eligible patients to nimodipine 30 mg three times a day or placebo. The primary outcome was any cognitive decline defined by the changes on the Mini-Mental State Examination (Delta MMSE <=-3) or vascular AD assessment scale cognitive subscale (Delta ADAS-cog >= 4) at 6 months. Secondary outcomes included any distribution shift of Delta ADAS-cog, Delta MMSE or cognitive improvement defined by Delta ADAS-cog <=-2, or Delta MMSE >= 0. The primary outcome in the nimodipine group and placebo group were similar for Delta MMSE <=-3 (4.18% and 7.22%, respectively, P = 0.15) and Delta ADAS-cog >= 4 (8.36% and 8.93% respectively, P = 0.88). The distribution shift of Delta ADAS-cog and Delta MMSE differed significantly between the two groups (P = 0.03 and P = 0.05 respectively). Cognitive improvement occurred in 55.4% in the nimodipine group and 43.6% in the placebo group measured by Delta ADAS-cog <=-2 (Odds Ratio, 1.54; 95% confidence interval [CI] 1.10-2.14, P < 0.01) or 84.0% and 74.6% respectively by Delta MMSE >= 0 (Odds Ratio, 1.79; 95% CI 1.18-2.70, P < 0.01). Nimodipine was associated with better cognitive function in the memory domain. The adverse events rate was similar in two groups. This study is registered with ClinicalTrials.gov, NCT01220622. Nimodipine did not show benefit to prevent cognitive decline in AIS patients with VaMCI, but improved cognition moderately, especially measured in the memory domain. (C) 2018 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.
Neuroprotective Effects of Magnesium Lithospermate B Against Subarachnoid Hemorrhage in Rats

Yucong Peng,Pingyou He,Linfeng Fan,Hangzhe Xu,Jianru Li,Ting Chen,Wu Ruan,Zhangqi Dou,Gao Chen

DOI: https://doi.org/10.1142/s0192415x18500647

2018-01-01

Abstract:Subarachnoid hemorrhage (SAH) is a severe cerebrovascular disease with few effective pharmacotherapies available. Salvia miltiorrhiza, a traditional Chinese medicinal herb, has been widely used to treat cardiovascular diseases for centuries. Recent studies have demonstrated that magnesium lithospermate B (MLB), a bioactive ingredient extracted from Salvia miltiorrhiza, exerts neuroprotective effects in several central nervous system insults. However, little is known about the role of MLB in SAH-induced brain injury and the exact molecular mechanism. In the current study, we studied the neuroprotective effects of MLB in SAH and explored the potential mechanism. Adult male Sprague-Dawley rats were subjected to an endovascular perforation process to produce an SAH model. MLB was administrated intraperitoneally at 30[Formula: see text]min after SAH with a dose of 25[Formula: see text]mg/kg or 50[Formula: see text]mg/kg. We found that administration of MLB significantly attenuated brain edema and neurological deficits after SAH. In addition, immunofluorescence staining demonstrated that MLB dose-dependently inhibited the activation of microglia and reduced neuronal apoptosis. Western blot analysis showed that MLB decreased the expression of inflammatory cytokine TNF-[Formula: see text] and pro-apoptotic protein cleaved caspase-3. More importantly, MLB increased the expression of SIRT1, while inhibited the acetylation of NF-[Formula: see text]B. Furthermore, pretreatment with sirtinol (a selective inhibitor of SIRT1) reversed all the aforementioned effects of MLB after SAH. In conclusion, our results indicated that MLB exerted robust neuroprotective effects against SAH via suppressing neuroinflammation and apoptosis. These neuroprotective effects of MLB against SAH might be exerted via regulating the SIRT1/NF-[Formula: see text]B pathway. MLB or the SIRT1/NF-[Formula: see text]B pathway could be a novel and promising therapeutic strategy for SAH management.
Safety and efficacy of magnesium-rich artificial cerebrospinal fluid for subarachnoid hemorrhage

Yawen Cheng,Xiangning Han,Wanfu Xie,Gaofeng Xu,Xiaobin Bai,Lei Qi,Linjuan Zhang,Rui Liu,Weihua Dong,Weiyi Feng,Chengsen Pang,Wei Zhang,Fude Liu,Xiangqi Cao,Yue Xu,Guogang Luo

DOI: https://doi.org/10.3389/fneur.2024.1376216

IF: 3.4

2024-03-29

Frontiers in Neurology

Abstract:Objectives: This study aimed to investigate the efficacy of using a newly formulated magnesium-rich artificial cerebrospinal fluid (MACSF) as an alternative to normal saline (NS) for intraoperative irrigation during aneurysm clipping in improving the prognosis of patients with Aneurysmal subarachnoid hemorrhage (aSAH). Methods: Patients with aSAH who underwent intraoperative irrigation with MACSF or NS during the clipping in the First Affiliated Hospital of Xi 'an Jiaotong University from March 2019 to March 2022 were selected as MACSF group and NS group, respectively. The primary prognostic indicators were the incidence of favorable outcomes (mRS 0–2). The secondary outcome measures included cerebral vasospasm (CVS), mortality, total hospital stay, and intensive care unit (ICU) stay. Safety was evaluated based on the occurrence rates of hypermagnesemia, meningitis, and hydrocephalus. Results: Overall, 34 and 37 patients were enrolled in the MACSF and NS groups, respectively. At 90 days after aSAH onset, the proportion of favorable prognosis in the MACSF group was significantly higher than that in the NS group ( p = 0.035). The incidence of CVS within 14 days after surgery was significantly lower in the MACSF group than that in the NS group ( p = 0.026). The mortality rate in the MACSF group was significantly lower than in the NS group ( p = 0.048). The median lengths of hospital stay ( p = 0.008) and ICU stay ( p = 0.018) were significantly shorter in the MACSF group than in the NS group. No significant differences were observed in safety measures. Conclusion: Using MACSF as an irrigation fluid for aneurysm clipping can significantly improve the 90-day prognosis of patients with aSAH, which may be related to the reduced incidence of CVS. Clinical trial registration: https://www.clinicaltrials.gov, identifier NCT04358445.

neurosciences,clinical neurology
Nimodipine vs. Milrinone – Equal or Complementary Use? A Retrospective Analysis

Jennifer Jentzsch,Svitlana Ziganshyna,Dirk Lindner,Helena Merkel,Simone Mucha,Stefan Schob,Ulf Quäschling,Karl-Titus Hoffmann,Robert Werdehausen,Dirk Halama,Khaled Gaber,Cindy Richter

DOI: https://doi.org/10.3389/fneur.2022.939015

IF: 3.4

2022-07-14

Frontiers in Neurology

Abstract:Background: Cerebral vasospasm (CVS) continues to account for high morbidity and mortality in patients surviving the initial aneurysmal subarachnoid hemorrhage (SAH). Nimodipine is the only drug known to reduce delayed cerebral ischemia (DCI), but it is believed not to affect large vessel CVS. Milrinone has emerged as a promising option. Our retrospective study focused on the effectiveness of the intra-arterial application of both drugs in monotherapy and combined therapy. Methods: We searched for patients with aneurysmal SAH, angiographically confirmed CVS, and at least one intra-arterial pharmacological angioplasty. Ten defined vessel sections on angiograms were assessed before and after vasodilator infusion. The improvement in vessel diameters was compared to the frequency of DCI-related cerebral infarction before hospital discharge and functional outcome reported as the modified Rankin Scale (mRS) score after 6 months. Results: Between 2014 and 2021, 132 intra-arterial interventions (144 vascular territories, 12 bilaterally) in 30 patients were analyzed for this study. The vasodilating effect of nimodipine was superior to milrinone in all intradural segments. There was no significant intergroup difference concerning outcome in mRS ( p = 0.217). Only nimodipine or the combined approach could prevent DCI-related infarction (both 57.1%), not milrinone alone (87.5%). Both drugs induced a doubled vasopressor demand due to blood pressure decrease, but milrinone alone induced tachycardia. Conclusions: The monotherapy with intra-arterial nimodipine was superior to milrinone. Nimodipine and milrinone may be used complementary in an escalation scheme with the administration of nimodipine first, complemented by milrinone in cases of severe CVS. Milrinone monotherapy is not recommended.

neurosciences,clinical neurology
Effects of early lumbar cistern drainage of cerebrospinal fluid and combination of edaravone and nimodipine on vasospasm, intracranial pressure, inflammatory factors in traumatic subarachnoid hemorrhage

Wenjie Tong,Yongliang Jiang,Bo Huang,Jun Fang

DOI: https://doi.org/10.4314/tjpr.v21i8.24

2022-09-25

Tropical Journal of Pharmaceutical Research

Abstract:Purpose: To investigate the effect of early lumbar cistern drainage (LCD) of cerebrospinal fluid (CSF) and combination of edaravone and nimodipine on vasospasm, intracranial pressure (ICP), serum inflammation, S100 and vascular endothelial growth factor (VEGF) levels in traumatic subarachnoid hemorrhage (tSAH). Methods: Treatment was administered to 136 patients divided into control group (n = 68) and study group (n = 68). Serum inflammation was determined by assessing the levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) while nitric oxide (NO), endothelin-1 (ET-1), S100 and VEGF levels were determined by enzyme-linked immunosorbent assay (ELISA). Serum C-reactive protein (CRP) level was measured by immunoturbidimetry. Perfusion weighted imaging was performed and the mean transit time (MTT), cerebral blood flow (CBF), cerebral blood volume (CBV), mean flow velocity (Vm) and pulsatility index (PI) were recorded. Glasgow coma scale (GCS) score and Montreal cognitive assessment (MoCA) score were used to compare the differences in therapeutic effect. Results: Compared with values before treatment, Vm, PI, NO, CBF, CBV, GCS score and MoCA score were significantly increased (p < 0.05), while ICP, serum levels of TNF-α, IL-6, CRP, ET-1, S100 and VEGF and MTT significantly decreased (p < 0.05). Therapeutic response rate of the study group (89.71 %) was higher than that of control group (66.18%) (p < 0.05). Conclusion: Early LCD of CSF and combination of edaravone and nimodipine reduces the degree of cerebral vasospasm and contribute to brain function recovery in the treatment of patients with tSAH. This therapeutic strategy requires further clinical trials before application in clinical practice.

pharmacology & pharmacy
Effect of Magnesium on Deterioration and Symptomatic Hemorrhagic Transformation in Cerebral Ischemia: An Ancillary Analysis of the FAST-MAG Trial

Shawn Fan,Michael Jang,May Kim-Tenser,Kristina Shkirkova,David S. Liebeskind,Sidney Starkman,Juan Pablo Villablanca,Scott Hamilton,Andrew Naidech,Jeffrey L. Saver,Nerses Sanossian,for the FAST-MAG Investigators and Coordinators

DOI: https://doi.org/10.1159/000528385

2023-01-05

Cerebrovascular Diseases

Abstract:Background: Magnesium (Mg) is a neuroprotectant in preclinical models. Lower serum Mg levels have been associated with symptomatic hemorrhagic transformation (HT) in patients with ischemic stroke. Early treatment of acute ischemic stroke with Mg may reduce rates of symptomatic HT. Methods: In this post hoc study of the Field Administration of Stroke Therapy Magnesium (FAST-MAG) trial, 1,245 participants with a diagnosis of cerebral ischemia received 20 g of Mg or placebo initiated in the prehospital setting. Posttreatment serum Mg level was measured for 809 participants. Cases of clinical deterioration, defined as worsening by ≥4 points on the National Institute of Health Stroke Scale (NIHSS), were imaged and evaluated for etiology. Symptomatic HT was defined as deterioration with imaging showing new hemorrhage. Results: Clinical deterioration occurred in 187 and symptomatic HT in 46 of 1,245 cases of cerebral ischemia. Rates of deterioration and symptomatic HT were not significantly lower in those who received Mg (15.7% vs. 14.4%, p = 0.591; 2.8% vs. 4.6%, p = 0.281). In cases where serum Mg level was obtained posttreatment, lower serum Mg level (#x3c;1.7 mg/dL) was associated with significantly higher rates of deterioration and symptomatic HT (27.5% vs. 15.5%, p = 0.0261; 11.6% vs. 3.65%, p = 0.00819). Conclusions: Treatment with Mg did not significantly reduce rates of clinical deterioration or symptomatic HT. Future analysis should address whether treatment with Mg could have influenced the subgroup with low serum Mg at baseline. Cerebrovasc Dis

peripheral vascular disease,clinical neurology
Magnesium and aspirin treatment in patients with subarachnoid haemorrhage

W. M. van den Bergh,A. Algra,G. J. E. Rinkel,on behalf of the MASH study group,W. M. Bergh,

DOI: https://doi.org/10.1007/s00415-009-0057-5

2009-01-24

Journal of Neurology

Abstract:ObjectiveAneurysm treatment with endovascular coiling is associated with a better outcome than neurosurgical clipping in patients with subarachnoid haemorrhage (SAH). The better outcome after coiling may decrease the risk reduction from other treatments in these patients, and thus may increase sample sizes for current or future neuroprotective trials. The influence of the method of aneurysm treatment was studied in our randomised MASH trial, which assessed in a factorial design the efficacy of magnesium and aspirin in preventing delayed cerebral ischaemia (DCI) and poor outcome.MethodsBetween November 2000 and January 2004 315 patients were enrolled in the trial; 55 of them had no aneurysm treatment and were excluded for the current analysis, 176 underwent neurosurgical and 84 endovascular treatment. The effect of treatment on the risk of DCI was assessed by means of Cox proportional hazards modelling and that of poor outcome by means of logistic regression analysis.ResultsThe hazard ratio of DCI with aspirin was 1.4 (95 % CI 0.3 – 1.7) after coiling and 1.9 (0.8 – 4.4) after clipping, and with magnesium 0.4 (0.1 – 1.2) after coiling and 0.8 (0.4 – 1.7) after clipping. The odds ratio of poor outcome with aspirin was 0.7 (0.2 – 2.9) after coiling and 0.8 (0.3 – 2.3) after clipping, and with magnesium 0.3 (0.1 – 1.0) after coiling and 0.8 (0.4 – 1.6) after clipping.ConclusionThis post hoc analysis does not suggest that medical treatments are less effective after endovascular than after neurosurgical treatment in patients with SAH, and thus do not support a need for adjusting sample size calculations in future trials.

clinical neurology
Streptococci as indices of pollution in well-waters.

W. Morris,R. Weaver

DOI: https://doi.org/10.1128/AEM.2.5.282-285.1954

1954-09-01

Applied Microbiology

Abstract:
The Therapeutic Effect of Nimodipine in Treatment of Severe Traumatic Brain Injuries with Subarachoid Hemorrhage

Zheng Guang-shu

Abstract:Objective To observe the therapeutic effect of nimodipine in treatment of severe cranio-cerebral trauma with subarachoid hemorrhage(SAH).Methods 96 patients with severe cranio-cerebral injury complicated by SAH(GCS3-8) were divided randomly into two groups.In nimodipine group 20mg nimodipine was injected intravenously bymicro-pump for 14 days,then 60mg by oral administration QID×7 days.In control group patients receives the same treatment measures but no nimodipine was given.Intracranial pressure and GCS were closely observed,GOS andcomplication were measured 4 months later.Results The GCS of nimodipine group from the first 4 days after treatment was significantly higher than that of the control group(P0.05);the intracranial pressure of the nimodipine group was slightly higher than the control group in the first 3 days,but there was no significant difference(P0.05).the incidences of cerebral infarction and hydrocephalus in the nimodipine group were significantly less than that of control group(P0.05),the incidence of delayed bleeding slightly more than the control group,but there was no significant difference(P0.05).The GOS of the nimodipine group after 4 months was significantly higher than the control group(P0.01).Conclusion Nimodipine has definitive therapeuric effect for severe cranio-cerebral trauma with SAH.

Medicine
Letter to editor: Serum concentration–guided intravenous magnesium sulfate administration for neuroprotection in patients with aneurysmal subarachnoid hemorrhage: A retrospective evaluation of a 12-year single-center experience.

Kainat Sohail,Syeda Mahrukh Fatima Zaidi

DOI: https://doi.org/10.1007/s10143-024-02431-y

IF: 2.8

2024-04-27

Neurosurgical Review

Abstract:This critique examines a 12-year retrospective study on serum magnesium concentration-guided administration of magnesium sulfate in 548 patients with aneurysmal subarachnoid hemorrhage (aSAH). The study reported that maintaining serum magnesium levels between 2 and 2.5 mmol/L reduced rates of delayed cerebral infarction and improved clinical outcomes. However, limitations due to its retrospective nature, single-center design, and unequal treatment group sizes may affect generalizability. Future multicentric randomized controlled trials are recommended to validate these findings and refine magnesium dosing strategies for aSAH treatment.

surgery,clinical neurology

The 1024 channel digital correlator receiver of the Gauribidanur radioheliograph

Initial clinical experience of vasodilatory effect of intra-cisternal infusion of magnesium sulfate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage

Association between third molar agenesis and craniofacial structure development.

Effect of intrathecal magnesium sulfate solution injection via a microcatheter in the cisterna magna on cerebral vasospasm in the canine subarachnoid haemorrhage model

Effects of intrathecal magnesium sulfate in severe pre- eclampsia patients undergoing cesarean section

High fibre diet in symptomatic diverticular disease of the colon.

Temporal profile of the effects of intracisternal injection of magnesium sulfate solution on vasodilation of spastic cerebral arteries in the canine SAH model

[Oxidative stress in patients on regular hemodialysis and peritoneal dialysis].

Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage

Early Intravenous Magnesium Sulfate and Its Impact on Cerebral Vasospasm as well as Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Retrospective Matched Case-Control Analysis

Magnesium Protects in Episodes of Critical Perfusion after Aneurysmal SAH

The Efficacy and Safety of Nimodipine in Acute Ischemic Stroke Patients with Mild Cognitive Impairment: a Double-Blind, Randomized, Placebo-Controlled Trial

Neuroprotective Effects of Magnesium Lithospermate B Against Subarachnoid Hemorrhage in Rats

Safety and efficacy of magnesium-rich artificial cerebrospinal fluid for subarachnoid hemorrhage

Nimodipine vs. Milrinone – Equal or Complementary Use? A Retrospective Analysis

Effects of early lumbar cistern drainage of cerebrospinal fluid and combination of edaravone and nimodipine on vasospasm, intracranial pressure, inflammatory factors in traumatic subarachnoid hemorrhage

Effect of Magnesium on Deterioration and Symptomatic Hemorrhagic Transformation in Cerebral Ischemia: An Ancillary Analysis of the FAST-MAG Trial

Magnesium and aspirin treatment in patients with subarachnoid haemorrhage

Streptococci as indices of pollution in well-waters.

The Therapeutic Effect of Nimodipine in Treatment of Severe Traumatic Brain Injuries with Subarachoid Hemorrhage

Letter to editor: Serum concentration–guided intravenous magnesium sulfate administration for neuroprotection in patients with aneurysmal subarachnoid hemorrhage: A retrospective evaluation of a 12-year single-center experience.